113 related articles for article (PubMed ID: 11092405)
1. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study.
Wimalawansa SJ
J Bone Miner Res; 2000 Nov; 15(11):2240-4. PubMed ID: 11092405
[TBL] [Abstract][Full Text] [Related]
2. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone.
Wimalawansa S; Chapa T; Fang L; Yallampalli C; Simmons D; Wimalawansa S
J Bone Miner Res; 2000 Jun; 15(6):1119-25. PubMed ID: 10841180
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
5. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
6. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
Ortiz Núñez DA; Mengchún López G; Hernández Marín I; Mendoza R; Ayala Ruíz AR
Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174
[TBL] [Abstract][Full Text] [Related]
7. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
Rosen HN; Parker RA; Greenspan SL; Iloputaife ID; Bookman L; Chapin D; Perlmutter I; Kessel B; Qvist P; Rosenblatt M
Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
[TBL] [Abstract][Full Text] [Related]
9. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
[TBL] [Abstract][Full Text] [Related]
10. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys.
Lees C; Shen V; Brommage R
Menopause; 2007; 14(1):97-105. PubMed ID: 17075430
[TBL] [Abstract][Full Text] [Related]
11. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
[TBL] [Abstract][Full Text] [Related]
12. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
13. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans.
Wimalawansa SJ
Ann N Y Acad Sci; 2007 Nov; 1117():283-97. PubMed ID: 18056048
[TBL] [Abstract][Full Text] [Related]
14. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
Cosman F; Nieves J; Shen V; Lindsay R
J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
[TBL] [Abstract][Full Text] [Related]
15. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
16. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
17. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
Pullerits R; d'Elia HF; Tarkowski A; Carlsten H
Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946
[TBL] [Abstract][Full Text] [Related]
18. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
[TBL] [Abstract][Full Text] [Related]
20. [Effect of estrogen replacement therapy on the serum osteocalcin level in the postmenopausal and castrated women].
Honjo S; Mizunuma H; Soda M; Igarashi M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1571-6. PubMed ID: 2555424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
